Journal article
Antiretroviral Initiation at ≥800 CD4 Cells/mm3Associated with Lower Human Immunodeficiency Virus Reservoir Size
TA Rasmussen, SK Ahuja, L Kuwanda, MJ Vjecha, F Hudson, L Lal, A Rhodes, J Chang, S Palmer, P Auberson-Munderi, H Mugerwa, R Wood, S Badal-Faesen, S Pillay, R Mngqibisa, A Larosa, J Hildago, K Petoumenos, C Chiu, J Lutaakome Show all
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2022
DOI: 10.1093/cid/ciac249
Abstract
Background: Identifying factors that determine the frequency of latently infected CD4+T cells on antiretroviral therapy (ART) may inform strategies for human immunodeficiency virus (HIV) cure. We investigated the role of CD4+ count at ART initiation for HIV persistence on ART. Methods: Among participants of the Strategic Timing of Antiretroviral Treatment Study, we enrolled people with HIV (PWH) who initiated ART with CD4+T-cell counts of 500-599, 600-799, or≥800 cells/mm3. After 36-44 months on ART, the levels of total HIV-DNA, cell-associated unspliced HIV-RNA (CA-US HIV-RNA), and two-long terminal repeat HIV-DNA in CD4+T cells were quantified and plasma HIV-RNA was measured by single-copy..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The study was funded by grants from Gilead Sciences Inc. (grant number CO-US-232-1804), Merck (grant number 51859), The Australian National Health and Medical Research Council (program grant APP149990, National Health Medical Research Council practitioner fellowship APP 1135851, and early career fellowship APP 1092160) and The Australian Centre for HIV and Hepatitis Virology Research. This work was also supported by the Delaney AIDS Research Enterprise (DARE) to Find a Cure (1U19AI096109 and 1UM1AI126611-01). The INSIGHT Washington International Coordinating Center provided in-kind effort and supplemental support to participating sites.